Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 7c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Eagle Pharmaceuticals (EGRX) PT Raised to $66 at RBC Capital
March 1, 2019 6:44 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $66.00 (from $64.00) while maintaining a Outperform rating following results.
"EGRX reported 4Q this morning that brought few material updates," Stanicky commented. "Notably, the coming weeks/months should bring... More
